ID

26717

Descripción

Study ID: 100601 Clinical Study ID: LPL100601 Study Title: LPL100601, A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00799903 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: darapladib Trade Name: darapladib Study Indication: Atherosclerosis Study part: Study conclusion

Palabras clave

Versiones (4)
  1. 9/10/17 9/10/17 -
  2. 13/10/17 13/10/17 -
  3. 23/10/17 23/10/17 -
  4. 11/1/18 11/1/18 -
Titular de derechos de autor

GlaxoSmithKline

Subido en

23 de octubre de 2017

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY-NC 3.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Study conclusion GSK study Chronic Coronary Heart Disease NCT00799903

Inglés

Study conclusion GSK study Chronic Coronary Heart Disease NCT00799903

1 formularios  
Study conclusion
Descripción

Study conclusion

1. Date of subject completion or withdrawal
Descripción

Date of subject completion or withdrawal

Tipo de datos

date

2. Was the subject withdrawn from the study before study reached GSK target number of primary clinical endpoints?
Descripción

subject withdrawal

Tipo de datos

text

3. Primary reason for withdrawal
Descripción

Item is not required

Tipo de datos

integer

If lost to Follow-up, provide comment
Descripción

Pre-defined sub-reasons are optional. The following primary reasons are optional : 2, 4 and 7. Pre-defined sub-reasons may/should be moved under appropriate primary reasons. See specific note for Group DSRS8.

Tipo de datos

text

If subject withdrew consent, provide comment
Descripción

Pre-defined sub-reasons are optional. The following primary reasons are optional : 2, 4 and 7. Pre-defined sub-reasons may/should be moved under appropriate primary reasons. See specific note for Group DSRS8.

Tipo de datos

text

If investigator site closed, provide comment
Descripción

Pre-defined sub-reasons are optional. The following primary reasons are optional : 2, 4 and 7. Pre-defined sub-reasons may/should be moved under appropriate primary reasons. See specific note for Group DSRS8.

Tipo de datos

text

4. For Data Managers or Monitors only: Tick or untick this box to require the investigator to re-sign the case book
Descripción

By ticking or unticking this box you are evoking a change to this form that will invalidate the original signature and will revert the form back to an unsigned state. This should be done when significant changes (e.g. those that require medical opinion or other significant situations) occur after the original signature. If the box is already ticked upon arrival on this form, unticking and submitting it accomplishes the same task as ticking and submitting it; that is, the signature will be invalidated in both instances. [hidden]. Item is not required.

Tipo de datos

integer

5. Q1
Descripción

[hidden] Item is not required

Tipo de datos

boolean

6. Q2
Descripción

[hidden] Item is not required

Tipo de datos

text

Volver a la parte superior de la página

Similar models

Study conclusion GSK study Chronic Coronary Heart Disease NCT00799903

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
Study conclusion
Date of subject completion or withdrawal
Item
1. Date of subject completion or withdrawal
date
Item
2. Was the subject withdrawn from the study before study reached GSK target number of primary clinical endpoints?
text
subject withdrawal
Code List
2. Was the subject withdrawn from the study before study reached GSK target number of primary clinical endpoints?
CL Item
No (N)
CL Item
Yes, complete primary reason for withdrawal (Y)
Item
3. Primary reason for withdrawal
integer
Primary reason for withdrawal
Code List
3. Primary reason for withdrawal
CL Item
Study closed/terminated (5)
CL Item
Lost to Follow-up (6)
CL Item
Withdrew consent (8)
CL Item
Investigator site closed (12)
lost to Follow-up comment
Item
If lost to Follow-up, provide comment
text
withdrawal of consent comment
Item
If subject withdrew consent, provide comment
text
investigator site closed comment
Item
If investigator site closed, provide comment
text
Item
4. For Data Managers or Monitors only: Tick or untick this box to require the investigator to re-sign the case book
integer
e-sign the case book
Code List
4. For Data Managers or Monitors only: Tick or untick this box to require the investigator to re-sign the case book
CL Item
1 (1)
Q1
Item
5. Q1
boolean
Item
6. Q2
text
Q2
Code List
6. Q2
CL Item
PF_SC_LOST (PF_SC_LOST)
CL Item
[?] PF_SC_DEATH ([?] PF_SC_DEATH)
CL Item
[?] PF_SC_SPONSORDECISION ([?] PF_SC_SPONSORDECISION)
CL Item
PF_SC_PHYSICIANDECISION (PF_SC_PHYSICIANDECISION)
CL Item
PF_SC_PATIENTDECISION (PF_SC_PATIENTDECISION)
CL Item
PF_SC_AE (PF_SC_AE)
CL Item
PF_SC_ALE (PF_SC_ALE)
CL Item
PF_SC_CRITERIA (PF_SC_CRITERIA)
CL Item
PF_SC_OTHER (PF_SC_OTHER)
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial